Intravenous Iron Drugs Market Projected to Reach US$ 7.4 Billion by 2034
核心洞察
The global intravenous iron drugs market is projected to grow from US$ 3.2 billion in 2024 to US$ 7.4 billion by 2034, at a CAGR of 8.8%.
Ferric carboxymaltose led the market with a 44.1% share in 2024, while chronic kidney disease (搜索) was the dominant application segment at 38.5%.
A 2025 real-world evaluation of ferric derisomaltose reported a 65.1% clinical response rate and a serious allergic reaction rate of just 0.04%.
The global intravenous iron drugs market is expected to reach approximately US$ 7.4 billion by 2034, up from US$ 3.2 billion in 2024, expanding at a compound annual growth rate (CAGR) of 8.8% during the forecast period from 2025 to 2034. The market's growth reflects rising demand for effective anemia management across chronic kidney disease (搜索), cancer-related anemia, heart failure (搜索), and inflammatory disorders requiring rapid iron replenishment.
Intravenous iron therapies provide faster hemoglobin improvement compared with oral iron supplements, making them increasingly preferred for patients with poor absorption, intolerance, or severe iron deficiency. The World Health Organization (WHO) estimates that anemia affects approximately 1.9 billion people globally, particularly women, children, and individuals with chronic diseases.
Market Segmentation and Leading Formulations
Ferric carboxymaltose dominated the market in 2024, capturing 44.1% of the global market share due to its favorable dosing benefits, shorter infusion duration, and reduced need for repeated hospital visits. Other formulations, including iron sucrose, iron derisomaltose, iron dextran, and sodium ferric gluconate, maintain demand through established clinical use, cost benefits, and specific therapeutic applications.
Chronic kidney disease (搜索) (CKD) emerged as the leading application segment in 2024, accounting for 38.5% of the global market share, supported by increasing anemia cases among CKD patients. Inflammatory bowel disease, cancer-related anemia, obstetric applications, heart failure (搜索), and perioperative care also contributed significantly.
The adult segment held the largest patient-type position in 2024 at 47.4%, while hospitals remained the dominant end-user segment at 48.7% due to their extensive use of intravenous iron therapies for complex anemia management.
Clinical Evidence Supporting Ferric Derisomaltose
A 2025 real-world evaluation of ferric derisomaltose intravenous iron therapy reported 2,468 patients treated across 2,775 infusion courses, with a mean administered dose of 1,244 mg per course. The treatment increased mean hemoglobin levels by 20.9 g/L and increased mean ferritin levels by 188.8 µg/L after follow-up assessment.
The same study showed that 65.1% of treatment courses (962/1,478) achieved a clinical response, defined as patients becoming non-anemic or achieving a hemoglobin increase of ≥20 g/L. Additionally, 33.4% of treatment courses (494/1,478) resulted in patients becoming non-anemic after therapy based on predefined hemoglobin thresholds.
Regarding safety, serious allergic reactions occurred in 1 out of 2,468 patients (0.04%) receiving ferric derisomaltose therapy. A clinical safety analysis reported serious or severe hypersensitivity reactions of 0.3% with ferric derisomaltose compared with 0.4% with iron sucrose in comparative trial populations. A pooled safety analysis reported overall adverse drug reaction rates of 8.6% for ferric derisomaltose and 9.0% for iron sucrose.
Expanding Applications in Heart Failure
The use of intravenous iron is expanding beyond anemia treatment into cardiovascular care. Clinical recommendations support IV iron therapy in heart failure (搜索) patients with iron deficiency, particularly when ferritin is below 100 ng/mL or TSAT is below 20%.
A 2025 evidence review of intravenous iron therapy in heart failure (搜索) reported that patients receiving ferric derisomaltose experienced serious adverse cardiac events in 36% of cases compared with 43% in usual-care groups, representing a 7 percentage-point reduction. Recent clinical evidence also showed intravenous iron reduced cardiovascular death or first hospitalization risk by approximately 20% in selected patients.
Regional Leadership and Recent Developments
North America maintained its leading position in 2024, accounting for more than 45.4% share with a market value of US$ 1.5 billion. The region's growth is supported by advanced healthcare infrastructure, strong clinical adoption, and increasing diagnosis of iron deficiency anemia (搜索) associated with chronic kidney disease (搜索), cancer, gastrointestinal disorders, and heart failure (搜索).
In 2025, CSL Vifor (搜索) continued strengthening its intravenous iron and nephrology-focused portfolio, maintaining focus on Ferinject® (ferric carboxymaltose). Viatris expanded its complex injectable medicine capabilities through the launch pathway for intravenous iron products, including iron sucrose and ferric carboxymaltose injection programs. In 2026, Pharmacosmos (搜索) continued supporting adoption of Monoferric® as a single-dose intravenous iron option, with the therapy evaluated in clinical trials involving 3,050 patients with iron deficiency anemia (搜索).
Emerging Trends
The market is shifting toward high-dose single infusion therapy, with ferric carboxymaltose and ferric derisomaltose capable of delivering doses of up to 1,000–2,000 mg in single or limited infusions. Healthcare organizations are strengthening intravenous iron treatment protocols using clinical evidence, with recent assessments reviewing data from 12 randomized controlled trials to support safer patient selection, dosing strategies, and monitoring practices.
Treatment decisions increasingly rely on measurable indicators such as hemoglobin, ferritin, and transferrin saturation, with three major biomarkers commonly used to evaluate iron deficiency status. These developments, combined with ongoing product innovations and regulatory approvals, are expected to create new opportunities for pharmaceutical companies operating in the intravenous iron drugs sector.